Solara Active Pharma Sciences Balance Sheet Health
Financial Health criteria checks 3/6
Solara Active Pharma Sciences has a total shareholder equity of ₹10.9B and total debt of ₹8.2B, which brings its debt-to-equity ratio to 75.3%. Its total assets and total liabilities are ₹22.9B and ₹12.0B respectively.
Key information
75.3%
Debt to equity ratio
₹8.20b
Debt
| Interest coverage ratio | n/a |
| Cash | ₹60.70m |
| Equity | ₹10.89b |
| Total liabilities | ₹12.01b |
| Total assets | ₹22.90b |
Recent financial health updates
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?
Mar 13
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?
Sep 30Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt
Jun 19Recent updates
The Market Lifts Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares 26% But It Can Do More
Sep 13Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 30% Bounce
Jul 20Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A Catch
Jun 05A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)
May 11Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price Jump
Apr 19Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?
Mar 13Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance Completely
Feb 23Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% Bounce
Jan 04Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share Price
May 12Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)
Nov 08Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?
Sep 30Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?
Aug 03Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt
Jun 19Newsflash: Solara Active Pharma Sciences Limited (NSE:SOLARA) Analysts Have Been Trimming Their Revenue Forecasts
Feb 17A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)
Dec 21Financial Position Analysis
Short Term Liabilities: SOLARA's short term assets (₹7.6B) do not cover its short term liabilities (₹10.5B).
Long Term Liabilities: SOLARA's short term assets (₹7.6B) exceed its long term liabilities (₹1.5B).
Debt to Equity History and Analysis
Debt Level: SOLARA's net debt to equity ratio (74.7%) is considered high.
Reducing Debt: SOLARA's debt to equity ratio has increased from 58.2% to 75.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable SOLARA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: SOLARA is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 4.7% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 02:09 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Solara Active Pharma Sciences Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Antique Stockbroking Ltd. |
| Kameswari V. S. Chavali | FirstCall Research |
| Rishabh Kale | Indsec Securities & Finance Ltd. |